Page 60«..1020..59606162..7080..»

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

Posted: June 4, 2024 at 2:49 am

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model, a widely used breast cancer risk assessment calculator.

The rest is here:
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

Posted in Global News Feed | Comments Off on Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Posted: June 4, 2024 at 2:49 am

FOSTER CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were each made as a material inducement to the employee’s acceptance of employment with Terns.

Excerpt from:
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Posted in Global News Feed | Comments Off on Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

DARZALEX® (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly…

Posted: June 4, 2024 at 2:49 am

88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with daratumumab subcutaneous formulation-based regimens in the Phase 3 PERSEUS study1

See original here:
DARZALEX® (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly...

Posted in Global News Feed | Comments Off on DARZALEX® (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly…

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed…

Posted: June 4, 2024 at 2:49 am

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

Original post:
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed...

Posted in Global News Feed | Comments Off on Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed…

Arvinas to Participate in Upcoming Investor Conferences

Posted: June 4, 2024 at 2:49 am

NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:

Read more:
Arvinas to Participate in Upcoming Investor Conferences

Posted in Global News Feed | Comments Off on Arvinas to Participate in Upcoming Investor Conferences

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Posted: June 4, 2024 at 2:49 am

Call scheduled for Tuesday, June 4, 2024 at 8:30 a.m. ET Call scheduled for Tuesday, June 4, 2024 at 8:30 a.m. ET

Go here to see the original:
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Posted in Global News Feed | Comments Off on Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Posted: June 4, 2024 at 2:49 am

June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:40 PM ET in Miami, FL.

See original here:
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Posted in Global News Feed | Comments Off on argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme

Posted: June 4, 2024 at 2:49 am

BASEL, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that it has received a non-dilutive award from the CF AMR Syndicate of up to £ 500,000, via a LifeArc funded Collaborative Discovery Programme (CDP) award, to support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).

Link:
BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme

Posted in Global News Feed | Comments Off on BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme

Chris Bumstead Receives Stem Cell ‘Longevity Treatment’ to Decrease Inflammation and ‘Slow Down Aging in the … – Fitness Volt

Posted: June 4, 2024 at 2:49 am

Chris Bumstead is pulling out all the stops to ensure he leaves Las Vegas, Nevada with a sixth Classic Physique Olympia title. In a recent Instagram post, Bumstead underwent a longevity-inspired stem cell treatment to decrease inflammation and slow aging in the body.

Chris Bumstead is back again this time for a longevity treatment, says Dr. Khan.

Despite suffering from an autoimmune disease, Chris Bumstead has reached remarkable heights as an IFBB Pro bodybuilder. Since 2018, he has reigned over the Classic Physique division, having acquired five consecutive victories at the Olympia show.

To compete at the highest level, Bumstead has taken significant measures to preserve his health, including stem cell therapy for kidney regeneration. Now, with his sights set on another prestigious title, he walked his fans through his latest experience with Dr. Khan.

Mainly, I have an autoimmune disease and stem cells are really good at decreasing inflammation and really good for the immune system and keeping that at bay.

So, when I saw Dr. Khan last year, it was the healthiest Ive ever been afterward. I just want to keep up with all that, make sure Im staying ahead of everything. Also, as a bodybuilder, I put my body through a lot of stress with a lot of inflammation, a lot of joint pain, a lot of this and a lot of that.

According to Bumstead, he switched to regenerative medicines like stem cells after prescription drugs were unable to fix his health problems. With fewer risks associated with the treatment, Bumstead felt more confident in proceeding in this direction.

I turned to regenerative medicine, biohacking the more natural side of things anything other than the traditional medicine a while ago when I was in Canada, I was given a few prescription drugs that were kind of like a bandaid not helping any of my issues.

After a wide variety of more natural ways and after finding Dr. Khan and learning about stem cells, I realize that theres a lot more benefits I can get from that with seemingly less risk as well, shared Chris Bumstead.

Dr. Khan explained that the procedure would help Bumstead during his prep but highlighted how beneficial it would be for him in retirement.

Not only for prep but just for general longevity, meaning after he retires from bodybuilding, which he inevitably will, he wants to continue living a healthy strong life and this is one of the best ways to do it, intravenous stem cells and exosomes, are engineered now to enhance our ability to survive.

Specifically, Dr. Khan revealed that Bumstead received follistatin gene therapy to decrease inflammation and slow down aging in the body.

Were also using follistatin gene therapy which can inhibit myostatin, but more importantly decrease inflammation and slow down aging in the body.

Bumstead hasnt been the only top-tier bodybuilder to experiment with stem cell treatments. After losing his title at the 2022 Mr. Olympia, Mamdouh Big Ramy Elssbiay underwent a stem cell procedure to regenerate nerve damage that has negatively impacted his physique.

As the most hunted man in the Classic Physique division, time will tell if the operation will aid Bumstead in his quest to earn his sixth Olympia title later this year when the show celebrates its 60th anniversary in Las Vegas, Nevada.

RELATED:Chris Bumstead Shares Intense High-Volume Workout for Bigger Arms in the 2024 Off-Season

Original post:
Chris Bumstead Receives Stem Cell 'Longevity Treatment' to Decrease Inflammation and 'Slow Down Aging in the ... - Fitness Volt

Posted in Nevada Stem Cells | Comments Off on Chris Bumstead Receives Stem Cell ‘Longevity Treatment’ to Decrease Inflammation and ‘Slow Down Aging in the … – Fitness Volt

The properties of absorbable scaffold harvested with human amniotic fluid stem cells on rat model: an innovation for … – Nature.com

Posted: June 4, 2024 at 2:49 am

Ethical approval

Experimental protocols and procedures were approved by Chang Gung Memorial Hospitals Institutional Animal Care and Use Committee (No. 2019062002), Institutional Board Review (IRB: 201800954B0) and funded by the National Science and Technology Council Grants (MOST 107-2314-B-182A-103-). The study period took place from August 1st, 2018 to January 31st, 2020.

All procedures involving humans were carried out in accordance with relevant guidelines and regulations, and approved by Institutional Board Review Chang Gung Memorial Hospital. Informed consent was obtained from all participants/donor.

All experimental procedures were performed under the supervision of a licensed veterinarian, in a manner consistent with the regulations of the National Institute of Health of Taiwan. All animal related procedures were approved by the Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital (IACUC Approval No.: CGMH2019062002). All methods involving animals are reported in accordance with ARRIVE guidelines.

The hAFSCs were obtained from freshly collected amniotic fluid by routine amniocentesis from healthy pregnant donors at 1520 gestational weeks. Cells were cultured in StemPro MSC Serum free medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad,CA) and incubated at 37C with 5% carbon dioxide. Culture medium was changed every 34days. The specific surface antigens of hAFSCs were characterized using flow cytometry analyses. The cultured cells were trypsinized and stained with phycoerythrin (PE)-conjugated antibodies against CD90 (BD PharMingen,CA). The cells were analyzed using the Calibur flow cytometer (Becton Dickinson, Heidelberg, Germany). Passage 4 to 6 hAFSCs were collected and prepared to a final concentration of 3106 cells/0.3mL Phosphate Buffer Solution (PBS). Thereafter, 3106 hAFSCs were seeded on a sterile mesh-scaffold and cultured for 3days prior transplantation. This is accordance to the previous work by Liang et al.12.

Three types of absorbable materials were compared, comprising AlloDerm RTM; PLGA mesh (VICRYL) and PDS mesh. The characteristic of each mesh is displayed in Table 1. Cell line from amniotic fluid stem cells was cultivated with basic fibroblast growth (bFGF). To measure the cells ability to proliferate, EdU Assay (Click-iTEdU Assay, Invitrogen, Life Technologies Corporation, Carlsbad, CA, USA) is incubated with hAFSC, and meshes-harvested with hAFSc. EdU Assay (5-ethynyl-2-deoxyuridine) works as a nucleoside analog of thymidine and is incorporated into DNA during active DNA synthesis. Procedure was performed in accordance to protocol (Supplementary, S1). DNA staining is performed for imaging and analysis. hAFSCs seeded mesh-scaffold were incubated at 37C in 5% CO2 for 60min, followed by Dulbeccos modified Eagle medium. MTS (5-(3-carboxymethoxyphenyl)-2-(4,5-dimethyl-thiazoly)-3-(4-sulfophenyl) tetrazolium, inner salt assay)13 colorimetric assay test were conducted on day 7 and day 14 for cell metabolic activity (Fig.1). DAPI (Santa Cruz Biotechnology, Santa Cruz, CA, USA) Stain for immunofluorescence imaging were also conducted on day 14. The most suitable mesh with hAFSC growth was determined by immunofluorescence assay and scanning electron microscopy (SEM) via LIVE/DEAD Viability/cytotoxicity Kit on day 7 and day 14. SEM enables direct microscopic imaging of the material properties on the surface sample, that offers adjustable magnification and large field depth. In this study, spot charge-coupled device color digital camera (Olympus DP72, Tokyo, Japan) was used to obtain immunohistochemistry images under 20objective (Olympus BX-51, Tokyo, Japan) and immunofluorescence under Leica TCS SP8X confocal laser scanning microscope (Leica Microsystem, Heidelberg, Germany) with appropriate filters for DAPI. Camera was interfaced with Image-Pro Plus Software (Media Cybernetics, Silver Spring, MD, USA). This is in accordance as previous study conducted by Liang et al.14.

Total of 28 SpragueDawley rats, with the mean age 12.31.7weeks old and weighing 298.227.1g were treated and cared for under the supervision of a licensed veterinarian, in a manner consistent with the regulations of the National Institute of Health of Taiwan. All animal related procedures were approved by the Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital (IACUC Approval No.: CGMH2019062002).

Seven groups were assigned: [1] sham control group with fascia operation; [2] AlloDerm implant; [3] PDS implant; [4] PLGA implant; [5] AlloDerm harvest with hAFSC (AlloDerm-SC); [6] PDS harvest with hAFSC (PDS-SC); and [7] PGLA harvest with hAFSC (PGLA-SC).

Rats were anesthetized with 2% Isoflurane mask inhalation. An abdominal midline incision of 4cm and subcutaneous blunt dissection to muscle were made. A 1.01.0cm full-thickness abdominal muscle fascia resected. Mesh measuring 2.02.0cm was fixated with continuous, absorbable suture (Polygactin, Vicryl 3/0) to cover the defect. Skin was then closed with running subcuticular absorbable sutures (Vicryl 3/0) (Fig.2). Sham control group with fascia operation underwent abdominal muscle fascia resection without mesh implantation. In the present study, the number of control rats was reduced in compliance with IACUCs recommendation. Total of 12 rats (week 1), 4 rats (week 2) and 12 rats (week 12) were sacrificed at respective weeks. The tissues were harvested at 12weeks, and meshes were retrieved for tensile properties characteristic and immuno-histological examination.

The mechanical properties of three absorbable mesh with and without AFSC meshes were estimated utilizing tensile test equipment (Lloyd, Ametek, Berwyn, PA, USA) (Fig.3). The maximum strengths of three absorbable mesh with and without AFSC were compared. The stretching speed was set at 100mm/min and the ultimate load and deformation were recorded.

Tensiometry for mechanical properties of the scaffolds.

The rats were euthanized with 3% isoflurane and then decapitated, in accordance and manner consistent with the regulations of the National Institute of Health of Taiwan and Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital.

Sample size calculation was done by using crude method based on law of diminishing return with the equation of E=total number of animals-total number of groups. After the calculation with (7 groups6 rats/group) (7groups)=35, suggesting the sample size for this study was adequate, and 6 rats were used for each group15. The data were analyzed and expressed as meanSD for continuous variables. Continuous data were compared among the groups by using one-way analysis of variance. To evaluate the effect of hAFSC among groups, chi-square test was performed with Fishers exact test. Probability value of<0.05 are statistically significant.

All procedures involving humans were carried out in accordance with relevant guidelines and regulations, and approved by Institutional Board Review Chang Gung Memorial Hospital. Informed consent was obtained from all participants/donor. All experimental procedures were performed under the supervision of a licensed veterinarian, in a manner consistent with the regulations of the National Institute of Health of Taiwan. All animal related procedures were approved by the Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital (IACUC Approval No.: CGMH2019062002). All methods involving animals are reported in accordance with ARRIVE guidelines.

More here:
The properties of absorbable scaffold harvested with human amniotic fluid stem cells on rat model: an innovation for ... - Nature.com

Posted in Stem Cells | Comments Off on The properties of absorbable scaffold harvested with human amniotic fluid stem cells on rat model: an innovation for … – Nature.com

Page 60«..1020..59606162..7080..»